Wesely received her Ph.D. in Biosciences from the Goethe University in Frankfurt, Germany in 2016 and subsequently completed her postdoctoral fellowship at the Icahn School of Medicine at Mount Sinai in New York, where she used acute myeloid leukemia (AML) patient-derived stem cells to investigate the role of leukemia stem cells in AML.
In her work at JAX-NYSCF, she applies CRISPR gene editing techniques to patient-derived cells to investigate drivers of various common and rare diseases. Additionally, her team focuses on using iPSC-derived heart cells (cardiomyocytes) to develop better population scale models and safety platforms.